
Effective Drug Delivery to The Brain
From neurodegeneration and stroke to brain cancers and mental disorders – many brain conditions are poorly medicated: limitations in drug-delivery prevent treating patients efficiently.
The main reason is the Blood Brain Barrier (BBB), which prevents most therapeutic molecules from reaching the brain – and severely limits the development and use of therapeutics for brain conditions. Biologics and RNA drugs in particular, despite their immense therapeutic potential, are unable to cross the BBB and address brain conditions.
At NucleoTech, we developed a unique platform to accelerate the discovery of game-changing carriers for brain delivery. Our carriers enable non-invasive and significantly more effective use of existing drugs. Furthermore, our innovative delivery carriers will pave the way for using Biologics and RNA drug classes in a new generation of treatments that leverage the latest breakthroughs in translational research on brain conditions.
With our carriers, we aim to offer treatment to previously untreatable brain conditions, changing the lives of millions.
Furthermore, Biologics and RNA drugs, despite their immense therapeutic potential, are unable to cross the BBB and address brain conditions. Our innovative delivery carriers will pave the way for using these drug classes in a new generation of treatments that leverage the latest breakthroughs in translational research on brain conditions.
Our Technology
In a recent breakthrough we were able to establish a novel, rapid, and cost-effective method for quantifying delivery efficiency in live animals. This game-changing method enables the first ever in-vivo screening for brain delivery carriers.
Screening in-vivo for carriers that efficiently overcome the diverse mechanisms that exclude entry by the BBB overcomes the main limitation in carrier development, transforming CNS drug-discovery.
We develop nanobodies (also called Single Domain Antibodies) as carriers that leverage the process of Receptor-Mediated Transcytosis for efficient brain delivery. They are selected for high in-vivo delivery potency, offer advantages in size, low immunogenicity, and compatibility with biologics and RNA drugs – today’s leading therapeutic classes.
Vision
At NucleoTech, we share a vision of breaking down technological barriers to promote global health
We tread paths less taken, believing that the best innovations emerge from nurturing creativity while keeping practical and agile
Our Team
Our team includes both scientific and operational expertise, with a track record in translational research and business development.
Founding Team

Uriah Bekenstein, PhD
CEO
Molecular neurobiologist
Biotech and IP strategy experience

Naftali Cohen
CBO
Startup management experience
Track record in scaling startups

Adi Koplovitz
COO
Economist and strategic leadership
Recognized in Israel's "40 under 40"
We are blessed with a strong R&D team comprised of 100% Post-PhD experienced scientists working hands-on, lead by BBB expert Dr. Shachar Dagan, previously of Harvard medical school.
Our Business Advisory gives us access to decades of experience in top level Pharma, Biotech and startup experience to help guide us along our journey.
Finally, our close scientific advisory consists of experts in the fields of Blood-Brain Barrier, Molecular neurobiology, and Nanobody design.
Research Team

Shachar Dagan, PHD
Head of Research

Tehila Dahan, PhD
R&D Manager

Alon Nudelman, PhD
Senior Scientist

Beata Tóth-Cohen, PhD
Research Advisor
Business Advisory

Dr. Pierre Morgon, LL.M, MBA
35 years of experience in the global life science industry, at the helm of international operations, in C-level positions at global level, in multinational corporations and as CEO of start-up companies

Dr. Christian Policard
Senior partner at Global Close Alliance (GCA), former Executive Vice President and member of the Global Strategy Committee of Sanofi. Participated in the creation of numerous companies in France, Israel and the USA

Lior Libman, PhD
Co-founder of numerous startups including Protos.bio and Blend.
LP at GTMfund, startup board member and mentor
Scientific Advisory

Prof. Hermona Soreq, PhD
Professor of Molecular Neuroscience; expert in neuronal signaling, stress, and neurodegenerative diseases. The Charlotte Schlesinger Professor of Molecular Neuroscience, winner of Landau Prize, ILANIT-Katzir Prize and the EMET Prize

Prof. Alon Friedman, MD. PhD
Professor of Neuroscience; renowned for discoveries of the link between BBB disruption and Epileptogenesis. Dennis Chair in Epilepsy Research at Dalhousie University. Michael prize for Epilepsy Research, and Foulkes Foundation Research Award

Prof. Pablo Blinder, PhD
Professor of neuroscience; expert in BBB physiology and imaging. Specifically Multi-modal hemodynamic imaging and multi-photon imaging. winner of Sieratzki and Krill Prizes

Prof. Niv Papo, PhD
Professor of structural biology; expert in development of high affinity proteins. winner of Krill Prize, amongst many

Prof. Ayal Ben Zvi, PhD
Professor of neuroscience; expert in BBB imaging, and use of super resolution microscopy